Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Neuroscience›Putamen
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Putamen

Neuroscience · NLM MeSH · updated 2026-10-29 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

The largest and most lateral of the basal ganglia lying between the lateral medullary lamina of the globus pallidus and the external capsule.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (874 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

The largest and most lateral of the basal ganglia lying between the lateral medullary lamina of the globus pallidus and the external capsule. It is part of the neostriatum and forms part of the lentiform nucleus along with the globus pallidus.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Putamens; Nucleus Putamen; Nucleus Putamens; Putamen, Nucleus; Putamens, Nucleus.

Where it fits in the MeSH classification

Broader topics
Neostriatum
See also
Putaminal Hemorrhage

Related concepts

  • Basal Ganglia
  • Globus Pallidus
  • External Capsule
  • Lentiform Nucleus

Research landscape

PubMed indexes 5,155 records tagged with the MeSH heading “Putamen” (counts retrieved 2026-10-29). 518 of them (10.0%) were published from 2020 onward, and the busiest period so far is through 1999 with 2,401 records.

Reviews account for 170 records (3.3%) and meta-analyses for 30. Randomized controlled trials number 49 (1.0%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 2,401 records; 2000-2009: 1,157 records; 2010-2019: 1,079 records; 2020 onward: 518 records2,401through 19991,1572000-20091,0792010-20195182020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19992,401
2000-20091,157
2010-20191,079
2020 onward518
Share of records by publication typeReviews: 3.3 percent; Meta-analyses: 0.6 percent; Randomized controlled trials: 1.0 percentReviews3.3% (170)Meta-analyses0.6% (30)Randomized controlled trials1.0% (49)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 5,155 PubMed records
TypeRecordsShare
Reviews1703.3%
Meta-analyses300.6%
Randomized controlled trials491.0%

Method: PubMed query "Putamen"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.

Reading the evidence in neuroscience

Neuroscience draws on tools with different strengths: cellular and animal work can manipulate circuits directly, while human imaging and electrophysiology observe the living brain at lower resolution. Small imaging studies are prone to false positives, and findings in animals do not always carry over to people. Clinical neurology and psychiatry rely on trials and cohort studies whose outcomes are often symptom scales. Check the species, the sample size, how the outcome was measured and whether results were replicated.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease
Whone AL, Boca M, Luz M, Woolley M, Mooney L, Dharia S, et al.
2019Research article
Design not recorded in structured metadata
103cc by
PMID 30829619 · DOI · PMC6597995
Aging is associated with increased collagen type IV accumulation in the basal lamina of human cerebral microvessels
Uspenskaia O, Liebetrau M, Herms J, Danek A, Hamann GF
2004Research article
Design not recorded in structured metadata
81cc by
PMID 15387892 · DOI · PMC523851
Somatic mtDNA mutation spectra in the aging human putamen
Williams SL, Mash DC, Züchner S, Moraes CT
2013Research article
Design not recorded in structured metadata
71cc by
PMID 24339796 · DOI · PMC3854840
Amygdala-putamen connectivity links gratitude to greater well-being
Liu G, Yang Y, Wang F, Kong F, Peng K, Sui J
2026Research article
Design not recorded in structured metadata
0cc by
PMID 42014361 · DOI · PMC13101003

Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease [1]

Research article Whone AL, Boca M, Luz M, Woolley M, Mooney L, Dharia S, et al. · · 2019 · cited 103 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundIntraputamenal glial cell line-derived neurotrophic factor (GDNF), administered every 4 weeks to patients with moderately advanced Parkinson's disease, did not show significant clinical improvements against placebo at 40 weeks, although it significantly increased [18F]DOPA uptake throughout the entire putamen.
Closing excerpt
ConclusionsThe aggregate study results, from the parent and open-label extension suggest that future testing with GDNF will likely require an 80- rather than a 40-week randomized treatment period and/or a higher dose.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (251 words)

BackgroundIntraputamenal glial cell line-derived neurotrophic factor (GDNF), administered every 4 weeks to patients with moderately advanced Parkinson's disease, did not show significant clinical improvements against placebo at 40 weeks, although it significantly increased [18F]DOPA uptake throughout the entire putamen.ObjectiveThis open-label extension study explored the effects of continued (prior GDNF patients) or new (prior placebo patients) exposure to GDNF for another 40 weeks.MethodsUsing the infusion protocol of the parent study, all patients received GDNF without disclosing prior treatment allocations (GDNF or placebo). The primary outcome was the percentage change from baseline to Week 80 in the OFF state Unified Parkinson's Disease Rating Scale (UPDRS) motor score.ResultsAll 41 parent study participants were enrolled. The primary outcome decreased by 26.7±20.7% in patients on GDNF for 80 weeks (GDNF/GDNF; N = 21) and 27.6±23.6% in patients on placebo for 40 weeks followed by GDNF for 40 weeks (placebo/GDNF, N = 20; least squares mean difference: 0.4%, 95% CI: -13.9, 14.6, p = 0.96). Secondary endpoints did not show significant differences between the groups at Week 80 either. Prespecified comparisons between GDNF/GDNF at Week 80 and placebo/GDNF at Week 40 showed significant differences for mean OFF state UPDRS motor (-9.6±6.7 vs. -3.8±4.2 points, p = 0.0108) and activities of daily living score (-6.9±5.5 vs. -1.0±3.7 points, p = 0.0003). No treatment-emergent safety concerns were identified.ConclusionsThe aggregate study results, from the parent and open-label extension suggest that future testing with GDNF will likely require an 80- rather than a 40-week randomized treatment period and/or a higher dose.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 30829619 · DOI · PMC6597995

Aging is associated with increased collagen type IV accumulation in the basal lamina of human cerebral microvessels [2]

Research article Uspenskaia O, Liebetrau M, Herms J, Danek A, Hamann GF · · 2004 · cited 81 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundMicrovascular alterations contribute to the development of stroke and vascular dementia.
Closing excerpt
However, hypertension was not proven to modulate these changes.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (219 words)

BackgroundMicrovascular alterations contribute to the development of stroke and vascular dementia. The goal of this study was to evaluate age and hypertension related changes of the basal lamina in cerebral microvessels of individuals, who died from non-cerebral causes.ResultsWe examined 27 human brains: 11 young and 16 old patients. Old patients were divided into two subgroups, those with hypertension (n = 8) and those without hypertension (n = 8). Basal lamina changes of the cerebral microvessels were determined in the putamen using antibodies against collagen type IV and by quantitative analysis of vessel number, total stained area of collagen, thickness of the vessel wall and lumen, and relative staining intensity using immunofluorescence. The total number of collagen positive vessels per microscopic field was reduced in old compared to young subjects (12.0+/-0.6 vs. 15.1+/-1.2, p = 0.02). The relative collagen content per vessel (1.01+/-0.06 vs. 0.76+/-0.05, p = 0.01) and the relative collagen intensity (233.1+/-4.5 vs. 167.8+/-10.6, p ConclusionsThe present data show age-related changes of the cerebral microvessels in sections of human putamen for the first time. Due to the accumulation of collagen, microvessels thicken and show a reduction in their lumen. Besides this, the number of vessels decreases. These findings might represent a precondition for the development of vascular cognitive impairment. However, hypertension was not proven to modulate these changes.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 15387892 · DOI · PMC523851

Somatic mtDNA mutation spectra in the aging human putamen [3]

Research article Williams SL, Mash DC, Züchner S, Moraes CT · · 2013 · cited 71 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The accumulation of heteroplasmic mitochondrial DNA (mtDNA) deletions and single nucleotide variants (SNVs) is a well-accepted facet of the biology of aging, yet comprehensive mutation spectra have not been described.
Closing excerpt
Our results reveal the complex manner in which the mitochondrial genome alters with age and provides a foundation for studies of other tissues and disease states.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (211 words)

The accumulation of heteroplasmic mitochondrial DNA (mtDNA) deletions and single nucleotide variants (SNVs) is a well-accepted facet of the biology of aging, yet comprehensive mutation spectra have not been described. To address this, we have used next generation sequencing of mtDNA-enriched libraries (Mito-Seq) to investigate mtDNA mutation spectra of putamen from young and aged donors. Frequencies of the "common" deletion and other "major arc" deletions were significantly increased in the aged cohort with the fold increase in the frequency of the common deletion exceeding that of major arc deletions. SNVs also increased with age with the highest rate of accumulation in the non-coding control region which contains elements necessary for translation and replication. Examination of predicted amino acid changes revealed a skew towards pathogenic SNVs in the coding region driven by mutation bias. Levels of the pathogenic m.3243A>G tRNA mutation were also found to increase with age. Novel multimeric tandem duplications that resemble murine control region multimers and yeast ρ(-) mtDNAs, were identified in both young and aged specimens. Clonal ∼50 bp deletions in the control region were found at high frequencies in aged specimens. Our results reveal the complex manner in which the mitochondrial genome alters with age and provides a foundation for studies of other tissues and disease states.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 24339796 · DOI · PMC3854840

Amygdala-putamen connectivity links gratitude to greater well-being [4]

Research article Liu G, Yang Y, Wang F, Kong F, Peng K, Sui J · · 2026

Abstract reading summary — source excerpts
Opening excerpt
IntroductionGratitude plays a crucial role in promoting affective well-being, yet the neural mechanisms underlying their relationship remains unclear.
Closing excerpt
This finding identifies a specific subcortical pathway through which grateful dispositions translate into emotional benefit and suggests a potential target for interventions aimed at improving mental health.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (193 words)

IntroductionGratitude plays a crucial role in promoting affective well-being, yet the neural mechanisms underlying their relationship remains unclear. Given the central role of the nucleus accumbens (NAcc) and amygdala in emotion and reward processing, this study investigated whether resting-state functional connectivity (RSFC) of these subcortical regions correlates with trait gratitude and mediates its association with affective well-being.MethodsResting-state fMRI data were collected from 363 young adults. Seed-based connectivity analyses identified NAcc and amygdala connectivity patterns associated with trait gratitude. Mediation analyses tested whether these patterns explained the association between gratitude and affective well-being.ResultsTrait gratitude was linked to stronger connectivity between the left NAcc and dorsomedial prefrontal cortex and left posterior superior temporal sulcus; between the right NAcc and left dorsolateral prefrontal cortex (DLPFC), right inferior temporal gyrus and bilateral fusiform; and between the right amygdala and right DLPFC, superior temporal gyrus, cerebellum, and putamen. Critically, the right amygdala-putamen connectivity mediated the relationship between gratitude and positive affective well-being.ConclusionsThe right amygdala-putamen RSFC links gratitude to greater affective well-being. This finding identifies a specific subcortical pathway through which grateful dispositions translate into emotional benefit and suggests a potential target for interventions aimed at improving mental health.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42014361 · DOI · PMC13101003

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Amygdala modulation of multiple memory systems: hippocampus and caudate-putamen [5]
    Packard MG, Teather LA · Neurobiol Learn Mem · 1998 · cited 207 times (Europe PMC)
  • Research article Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies [6]
    Fusar-Poli P, Meyer-Lindenberg A · Schizophr Bull · 2013 · cited 188 times (Europe PMC)
  • Research article The role of the putamen in language: a meta-analytic connectivity modeling study [7]
    Viñas-Guasch N, Wu YJ · Brain Struct Funct · 2017 · cited 133 times (Europe PMC)
  • Research article Consistent decreased activity in the putamen in Parkinson's disease: a meta-analysis and an independent validation of resting-state fMRI [8]
    Wang J, Zhang JR, Zang YF, Wu T · Gigascience · 2018 · cited 67 times (Europe PMC)
  • Research article Modality-specific overlaps in brain structure and function in obsessive-compulsive disorder: Multimodal meta-analysis of case-control MRI studies [9]
    Picó-Pérez M, Moreira PS, de Melo Ferreira V, Radua J, Mataix-Cols D, Sousa N, et al. · Neurosci Biobehav Rev · 2020 · cited 58 times (Europe PMC)
  • Research article What excitotoxin kills striatal neurons in Huntington's disease? Clues from neurochemical studies [10]
    Perry TL, Hansen S · Neurology · 1990 · cited 58 times (Europe PMC)

References

  1. Whone AL, Boca M, Luz M, Woolley M, Mooney L, Dharia S, et al.. Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease. . 2019. PMID 30829619 · DOI · PMC6597995
  2. Uspenskaia O, Liebetrau M, Herms J, Danek A, Hamann GF. Aging is associated with increased collagen type IV accumulation in the basal lamina of human cerebral microvessels. . 2004. PMID 15387892 · DOI · PMC523851
  3. Williams SL, Mash DC, Züchner S, Moraes CT. Somatic mtDNA mutation spectra in the aging human putamen. . 2013. PMID 24339796 · DOI · PMC3854840
  4. Liu G, Yang Y, Wang F, Kong F, Peng K, Sui J. Amygdala-putamen connectivity links gratitude to greater well-being. . 2026. PMID 42014361 · DOI · PMC13101003
  5. Packard MG, Teather LA. Amygdala modulation of multiple memory systems: hippocampus and caudate-putamen. Neurobiol Learn Mem. 1998. PMID 9619995 · DOI
  6. Fusar-Poli P, Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies. Schizophr Bull. 2013. PMID 22282454 · DOI · PMC3523905
  7. Viñas-Guasch N, Wu YJ. The role of the putamen in language: a meta-analytic connectivity modeling study. Brain Struct Funct. 2017. PMID 28585051 · DOI
  8. Wang J, Zhang JR, Zang YF, Wu T. Consistent decreased activity in the putamen in Parkinson's disease: a meta-analysis and an independent validation of resting-state fMRI. Gigascience. 2018. PMID 29917066 · DOI · PMC6025187
  9. Picó-Pérez M, Moreira PS, de Melo Ferreira V, Radua J, Mataix-Cols D, Sousa N, et al.. Modality-specific overlaps in brain structure and function in obsessive-compulsive disorder: Multimodal meta-analysis of case-control MRI studies. Neurosci Biobehav Rev. 2020. PMID 32006553 · DOI
  10. Perry TL, Hansen S. What excitotoxin kills striatal neurons in Huntington's disease? Clues from neurochemical studies. Neurology. 1990. PMID 1967491 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-29.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Globus PallidusNeuroscience
  • Basal GangliaNeuroscience
  • Nucleus AccumbensNeuroscience
  • Subthalamic NucleusNeuroscience
  • Caudate NucleusNeuroscience
  • Locus CoeruleusNeuroscience

All 110 articles in Neuroscience →

At a glance

5,155
PubMed records on this heading
10%
published since 2020
170
review articles
49
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-29; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Globus PallidusNeuroscience
  • Basal GangliaNeuroscience
  • Nucleus AccumbensNeuroscience
  • Subthalamic NucleusNeuroscience
  • Caudate NucleusNeuroscience

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support